WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Horizon Pharma plc
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
AMPEL BioSolutions | December 05, 2017
AMPEL BioSolutions, a leading biomedical research firm based in Charlottesville, Va., Horizon Pharma plc and The Lupus Research Alliance today announced the launch of the RIFLE (RAYOS (delayed release prednisone) Inhibits Fatigue in Lupus Erythematosus) trial for patients with Systemic Lupus Erythematosus (SLE). The RIFLE trial will utilize Horizon Pharma's proprietary prednisone delayed-release tablets, RAYOS, to address the daily cycling of cortisol and inflammatory mediators known a...
Horizon Pharma plc | April 11, 2019
Horizon Pharma plc (NASDAQ:HZNP) today announced it has been selected as one of the 2019 Best Workplaces in Health Care and Biopharma by Great Place to Work® and FORTUNE Magazine. The company has also been awarded a 2019 Best Places to work in Chicago designation by Crain's Chicago Business. "It is an honor to receive these two prestigious awards," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "At Horizon, we believe in givin...
Pharmacy Business | January 14, 2020
The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...
Business Wire Press Releases | January 16, 2020
Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...
Article
infographic
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE